PASG
HEALTHCAREPassage Bio Inc
$4.12-0.15 (-3.51%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PASG Today?
No stock-specific AI insight has been generated for PASG yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.95$20.00
$4.12
Fundamentals
Market Cap$13M
P/E Ratio—
EPS$-14.35
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume190K
Avg Volume (10D)—
Shares Outstanding3.2M
PASG News
17 articles- Sector Update: Health Care Stocks Softer Late AfternoonYahoo Finance·Apr 21, 2026
- Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush SaysYahoo Finance·Apr 21, 2026
- Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer SaysYahoo Finance·Apr 21, 2026
- Intel upgraded, Reddit initiated: Wall Street's top analyst callsYahoo Finance·Apr 21, 2026
- Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate UpdatesYahoo Finance·Apr 20, 2026
- Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business HighlightsYahoo Finance·Mar 3, 2026
- Passage Bio to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 19, 2026
- Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business HighlightsYahoo Finance·Nov 10, 2025
- Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation ConferenceYahoo Finance·Nov 5, 2025
- Passage Bio to Participate in Chardan’s 9th Annual Genetic Medicines ConferenceYahoo Finance·Oct 14, 2025
- Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a BetYahoo Finance·Sep 1, 2025
- Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Aug 28, 2025
- Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to TradeYahoo Finance·Aug 15, 2025
- Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business HighlightsYahoo Finance·Aug 12, 2025
- Passage Bio Announces 1-for-20 Reverse Stock SplitYahoo Finance·Jul 10, 2025
- Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program UpdateYahoo Finance·Jun 23, 2025
- Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business HighlightsYahoo Finance·May 13, 2025
All 17 articles loaded
Price Data
Open$5.06
Previous Close$4.27
Day High$5.16
Day Low$4.83
52 Week High$20.00
52 Week Low$3.95
52-Week Range
$3.95$20.00
$4.12
Fundamentals
Market Cap$13M
P/E Ratio—
EPS$-14.35
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume190K
Avg Volume (10D)—
Shares Outstanding3.2M
About Passage Bio Inc
Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company is headquartered in Philadelphia, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—